Ocugen, Inc. (OCGN)
1.025
0.00 (0.00%)
USD |
NASDAQ |
Sep 14, 12:08
Ocugen Enterprise Value : 333.76M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 333.76M |
| September 10, 2026 | 335.46M |
| September 09, 2026 | 349.02M |
| September 08, 2026 | 438.86M |
| September 04, 2026 | 449.04M |
| September 03, 2026 | 445.65M |
| September 02, 2026 | 435.47M |
| September 01, 2026 | 438.86M |
| August 31, 2026 | 438.86M |
| August 28, 2026 | 435.47M |
| August 27, 2026 | 452.43M |
| August 26, 2026 | 465.99M |
| August 25, 2026 | 462.60M |
| August 24, 2026 | 449.04M |
| August 21, 2026 | 459.21M |
| August 20, 2026 | 459.21M |
| August 19, 2026 | 489.72M |
| August 18, 2026 | 442.26M |
| August 17, 2026 | 454.12M |
| August 14, 2026 | 445.65M |
| August 13, 2026 | 445.65M |
| August 12, 2026 | 462.60M |
| August 11, 2026 | 452.43M |
| August 10, 2026 | 432.08M |
| August 07, 2026 | 421.91M |
| Date | Value |
|---|---|
| August 06, 2026 | 408.35M |
| August 05, 2026 | 421.91M |
| August 04, 2026 | 432.08M |
| August 03, 2026 | 411.74M |
| July 31, 2026 | 404.96M |
| July 30, 2026 | 415.13M |
| July 29, 2026 | 391.40M |
| July 28, 2026 | 408.35M |
| July 27, 2026 | 415.13M |
| July 24, 2026 | 398.18M |
| July 23, 2026 | 418.52M |
| July 22, 2026 | 425.30M |
| July 21, 2026 | 428.69M |
| July 20, 2026 | 438.86M |
| July 17, 2026 | 449.04M |
| July 16, 2026 | 452.43M |
| July 15, 2026 | 472.77M |
| July 14, 2026 | 472.77M |
| July 13, 2026 | 465.99M |
| July 10, 2026 | 486.33M |
| July 09, 2026 | 486.33M |
| July 08, 2026 | 496.50M |
| July 07, 2026 | 496.50M |
| July 06, 2026 | 493.11M |
| July 02, 2026 | 499.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Anika Therapeutics, Inc. | 266.01M |
| Gilead Sciences, Inc. | 199.64B |
| MannKind Corp. | 1.487B |
| Vertex Pharmaceuticals, Inc. | 124.70B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.88M |
| Revenue (Quarterly) | 1.488M |
| Total Expenses (Quarterly) | 26.36M |
| EPS Diluted (Quarterly) | -0.0734 |
| Gross Profit Margin (Quarterly) | 60.62% |
| Profit Margin (Quarterly) | -1.67K% |
| Earnings Yield | -24.85% |
| Normalized Earnings Yield | -23.98 |